Why steroids work in pemphigus, and why they stop
Before corticosteroids, pemphigus vulgaris was a disease people died of. Whatever else you read on this page, and whatever we say about the harm steroids do, keep that sentence in view. Steroids are the reason this disease is survivable. Nothing in this article is an argument against taking them.
It is an argument for understanding what they are actually doing — because the way they work explains, precisely, why they eventually stop.
What a corticosteroid actually does
A glucocorticoid crosses into the cell and binds the glucocorticoid receptor. The complex moves into the nucleus and does two things:
- Transrepression. It shuts down the master inflammatory transcription factors — NF-kB and AP-1. Transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF), chemokines and adhesion molecules collapses.
- Transactivation. It switches on anti-inflammatory genes.
That is why the improvement is fast. In pemphigoid, the eosinophil and mast-cell driven cascade at the dermal-epidermal junction is switched off. In pemphigus, the inflammatory amplification that follows antibody binding is switched off — and there is evidence that steroids also act directly on keratinocyte signalling, blunting the acantholytic cascade that pulls the cells apart. This is one reason skin can improve before there is any measurable fall in antibody.
Then, much more slowly, over weeks: reduced B-cell survival signalling, and reduced antibody production. Titres fall. Slowly. Incompletely.
The asymmetry that explains everything
Steroids suppress the consequences of the autoantibody quickly. They reduce the production of the autoantibody slowly, partially, and never completely.
The plasma cells manufacturing your anti-desmoglein or anti-BP180 antibody — particularly the long-lived ones sitting in bone marrow — are relatively resistant to corticosteroid. The drug puts out the fire. It does not remove the arsonist.
So when the dose comes down, the suppression comes off a machine that is still running. The antibody is still being made. The disease returns.
When you relapse on a taper, you have not failed. Your discipline is not the variable. That is the pharmacology of the drug you were given.
Why they seem to "stop working"
"It doesn't work like it used to" is one of the most common things we hear, and it covers several genuinely different mechanisms. It is worth knowing which one is happening to you, because they have different answers.
1. The driver was never touched. As above. The disease is unchanged; only its expression was suppressed. This is not the drug failing — it is the drug doing exactly what it does, and no more.
2. Steroid resistance at the receptor. Chronic inflammation and oxidative stress reduce the activity of HDAC2, an enzyme the glucocorticoid receptor needs in order to shut down inflammatory genes. Certain inflammatory cytokines lower the receptor's binding affinity. An alternative receptor form, GR-beta, can be upregulated and act as a decoy. The result: the same milligram does less than it did.
3. Efflux. Drug transporter proteins on lymphocytes can pump glucocorticoid back out of the cell. The drug arrives and leaves.
4. Epitope spreading. The immune response broadens over time. Someone with antibodies against desmoglein 3 alone may develop antibodies against desmoglein 1, and with them, skin disease on top of mouth disease. The drug has not changed. The disease has become a bigger target.
5. The ratchet. In practice, "stopped working" often does not mean no effect. It means: the dose now required to hold the disease costs more than the disease does. The drug still works. You just cannot afford what it takes.
What conventional medicine does about it — and what you may not have been told
This is the section we would most like a frightened patient to read, because it is not our treatment we are recommending here.
Rituximab, given with a steroid course, is now first-line in current guidance for moderate-to-severe pemphigus vulgaris. It depletes CD20-positive B cells — the cells that would go on to make the antibody. It is aimed at the source rather than the smoke, and it changed what is achievable in this disease.
There are also steroid-sparing drugs — azathioprine, mycophenolate mofetil, methotrexate — used exactly because of everything described above. In bullous pemphigoid, potent topical corticosteroid and doxycycline are established options that avoid loading a frail elderly person with high-dose oral steroid. Other approaches, including intravenous immunoglobulin and newer targeted drugs, exist for refractory disease.
If you have been on a steroid ratchet for years and rituximab has never been discussed with you, that is a question for your dermatologist. Ask it. Take it to a specialist centre if you have to. That question may do more for you than anything else you read tonight — including this page.
The rule that does not bend
You do not reduce or stop a steroid on your own, and never because of something you read.
Abrupt withdrawal after prolonged use risks adrenal crisis, because your own adrenal glands have stopped producing cortisol on demand. In active pemphigus, dropping immunosuppression risks a severe flare of a disease that can kill. We do not adjust, taper, substitute or discontinue any prescription. Steroids, rituximab, azathioprine, mycophenolate, dapsone, doxycycline — you continue them. Every change is made by the doctor who prescribed them.
If anything on this site ever appears to say otherwise, it is wrong, and you should ignore it.
So where does EPOH fit?
Not as a steroid substitute. We will say that as bluntly as we can, because the fantasy of replacing steroids with herbs is what gets people hospitalised.
EPOH is entirely formulation-based: oral compounds and topical preparations, couriered to you and taken at home. There is no procedure, no in-clinic therapy, and no clinic visit at any stage. It runs alongside your dermatologist's treatment, never instead of it.
It runs in one sequence — LIFES — and the sequence is the medicine:
- Phase L — Lowering Inflammatory Load
- Phase I — Internal Healing & Gut Repair
- Phase F — Functional Detox & Immune Balancing
- Phase E — External Care & Local Reversal (topical preparations applied at home)
- Phase S — Sustaining Remission
Look again at the mechanism above and you can see where an adjunct could plausibly matter, and where it plainly cannot. It cannot delete a long-lived plasma cell clone; rituximab is the drug aimed at that. Where it may matter is the inflammatory load and the internal terrain in which that immune response is being sustained — and, above all, the window in which relapse happens: the taper, and the months after B cells return. That window is exactly where conventional treatment does the least and where you are most alone.
And the timing rule, because it is the reason people get hurt: Phase F, run before L and I are stable, mobilises internal load faster than the system can clear it, and the condition worsens. Everyone who began Ayurvedic treatment with a "cleanse" or a "detox" and flared is evidence of that rule. The timing was wrong, not the approach.
What we will not claim
We cannot tell you that EPOH will let you come off steroids, and we will not say it. Your taper is your dermatologist's decision, made on your clinical picture and your titres. We do not promise a cure. We aim at sustained remission.
The first four to eight weeks are internal work; no visible skin change should be expected then. From months two to four the disease should begin to change. Stable remission is assessed from month eight.
The measures we hold ourselves to are the ones you can check: new lesion count, time for an erosion to close, itch score, mucosal pain, antibody titre trend — and whether your dermatologist finds you easier to taper. That last one is their judgment, not ours, and we will not claim credit for it without their agreement.
